Fasiha Fatima

Prof. Dr. Fasiha Fatima


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2023 in Pakistan Journal of Health Sciences
Verified
Journal Article
Open access
PDF file
ZAZubia Aziz
Zubia Aziz
ASArisha Sohail
Arisha Sohail
MSMadiha Soban
Madiha Soban
SSSyed Muhammad Huzaifah Shah
Syed Muhammad Huzaifah Shah
FFFasiha Fatima
Fasiha Fatima
ZHZeba Haque
Zeba Haque
COVID-19 pandemic imposed sudden changes in lifestyle with consequent altered metabolic status. Metabolic Syndrome is described as an altered metabolic profile of insulin resistance, dyslipidemia, hypertension, and central obesity which raises type 2 Diabetes Mellitus and cardiovascular disease danger at an early age. Objective: To analyze COVID-19 era status of obesity, hypertension, impaired glucose tolerance, dyslipidemia and metabolic syndrome in young adults. Methods: This was a cross-sectional study. 245 university students of either gender with ages 19–25 years were included. The lipid profile, fasting blood sugar and serum insulin was performed by kit method. The insulin resistance was determined by calculating the ratio of fasting glucose to insulin. SPSS version number 24.0 was used to analyze the data. Results: Metabolic syndrome's prevalence in overweight and obese subjects was found to be 36%. The most prevalent risk factor of Metabolic syndrome was raised blood pressure (60%) followed by insulin resistance (57%) and dyslipidemia (40%). The positive coefficient correlations were found for all Metabolic syndrome risk factors in general except HDL. The multivariate regression analysis evidenced that the BMI and WHR were the significant predictors of Metabolic syndrome risk factors. Conclusion: The COVID-19 restrictions consequences call for an urgency to effectively address e metabolic and related problems, especially among young individuals.

25 June 2026 in BMC Endocrine Disorders
Verified
Journal Article
Open access
PDF file
FFFasiha Fatima
Fasiha Fatima
AFAsher Fawwad
Asher Fawwad
ABAbdul Basit
Abdul Basit
EAEraj Abbas
Eraj Abbas
RARahima Aftab
Rahima Aftab
Patients with Type 2 diabetes mellitus (T2DM) are at increased risk of atherosclerotic cardiovascular disease, and coronary artery calcium score (CACS) ser

27 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
RARahima Aftab
Rahima Aftab
AFAsher Fawwad
Asher Fawwad
EAEraj Abbas
Eraj Abbas
RNRuqaya nangrejo
Ruqaya nangrejo
FFFasiha Fatima
Fasiha Fatima
Syed M. ShahidSyed M. Shahid
Syed M. Shahid
Background/Objectives: The rising global burden of type 2 diabetes mellitus (T2DM) demands multifaceted and more effective treatment strategies beyond monotherapy to achieve optimal metabolic control. The study aimed to evaluate the integrated effects of SGLT2 inhibitors and metformin in newly diagnosed T2DM patients on biochemical parameters, clinical outcomes and hormonal changes. Methods: This prospective longitudinal study was conducted at the Department of Biochemistry, Baqai Medical University, in collaboration with the Baqai Institute of Diabetology and Endocrinology. A total of 120 newly diagnosed T2DM patients were enrolled and stratified into three groups (n = 40): Group 1 (SGLT2 inhibitors only), Group 2 (SGLT2 inhibitors + metformin), and Group 3 (metformin only). Patients were followed for six months with data collection at baseline, at 3 months and 6 months. Anthropometric indices (weight, BMI, waist and hip circumferences, WHR), biochemical markers (FBS, HbA1c, lipid profile, uric acid, serum creatinine, HOMA-IR), and hormonal levels (insulin, glucagon) were assessed at baseline, first follow-up, and second follow-up. ANOVA, post hoc, Bonferroni and Tukey’s tests were applied; p-value < 0.05 was considered significant. Results: The findings indicate that Group 2 showed the greatest improvement in anthropometric parameters, particularly waist and hip circumferences (p < 0.01). Group 3 demonstrated the most significant improvement in glycemic indices and lipid profile (p < 0.01). HOMA-IR significantly decreased in Group 3 from baseline to the first follow-up (p < 0.01). While insulin levels remain insignificantly different among all groups. Glucagon levels declined significantly from baseline to the second follow-up in all groups, with a more pronounced decrease in Group 3 (p < 0.01). Serum creatinine and uric acid levels showed significant reductions from baseline to the second follow-up in Group 1 and Group 2 (p < 0.05). However, given the observational design, these associations should not be interpreted as causal evidence of renoprotection. Conclusions: Within the limitations of this observational study, early differences among treatment regimens were observed, though metabolic outcomes became statistically comparable across groups by six months. These hypothesis-generating findings suggest potential benefits of early combination therapy that require confirmation in randomized controlled trials. Given the substantial within-group variability and non-randomized design, no definitive conclusions about therapeutic associations can be drawn from these data.